Triple therapy with budesonide/glycopyrrolate/formoterol fumarate to prevent chronic obstructive pulmonary disease exacerbations has been shown to be more efficacious than single and dual agent treatments. A retrospective observational administrative claims database study (2019-2022) compared the temporal use (prompt, delayed, and very delayed) of triple therapy following moderate and severe exacerbations. Prompt treatment was associated with fewer exacerbations, reduced healthcare resource use, and costs.